Janux Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $23.90 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $24.36, a 43.18% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $42.87, a 112.12% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $20.21, a 25.61% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $16.09, a 19.54% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $27.84, a 112.52% increase from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $13.10, a 1.13% decline from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $13.25, a 4.47% decline from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $13.87, a 125.16% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.90 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $24.36 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $27.84 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $32.76 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $41.60 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $42.87 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $13.10 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $15.36 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $17.00 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $20.21 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $13.25 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $13.71 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $16.11 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $16.09 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $13.87 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $14.77 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $13.46 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $13.46 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $6.16 10-K · filed 2022-03-18 | |||
| 2021-09-30 | $6.26 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |